{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T11:50:21Z","timestamp":1783770621999,"version":"3.55.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s10072-020-04975-5","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T17:04:03Z","timestamp":1618506243000},"page":"3427-3430","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pregnancy outcomes in alemtuzumab treated women with multiple sclerosis: a case series"],"prefix":"10.1007","volume":"42","author":[{"given":"Russo Cinzia","family":"Valeria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanzillo","family":"Roberta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacc\u00e0","family":"Francesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moccia","family":"Marcello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carotenuto","family":"Antonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brescia Morra","family":"Vincenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,15]]},"reference":[{"key":"4975_CR1","unstructured":"European Medicine Agency Lemtrada: summary of product characteristics. 2017"},{"issue":"Suppl","key":"4975_CR2","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1002\/ana.410360712","volume":"36","author":"O Abramsky","year":"1994","unstructured":"Abramsky O (1994) Pregnancy and multiple sclerosis. Ann Neurol 36(Suppl):S38\u2013S41. https:\/\/doi.org\/10.1002\/ana.410360712","journal-title":"Ann Neurol"},{"issue":"11","key":"4975_CR3","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1212\/WNL.0000000000004354","volume":"89","author":"AJ Coles","year":"2017","unstructured":"Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung HP, Havrdova E, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Chirieac MC, Jody D, Xenopoulos P, Hogan RJ, Panzara MA, Arnold DL, Care MS II, Investigators C (2017) Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings. Neurology 89(11):1117\u20131126. https:\/\/doi.org\/10.1212\/WNL.0000000000004354","journal-title":"Neurology"},{"issue":"9856","key":"4975_CR4","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","volume":"380","author":"JA Cohen","year":"2012","unstructured":"Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA, investigators C-MI (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380(9856):1819\u20131828. https:\/\/doi.org\/10.1016\/S0140-6736(12)61769-3","journal-title":"Lancet"},{"issue":"14","key":"4975_CR5","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1212\/WNL.0b013e31824e8ee7","volume":"78","author":"AJ Coles","year":"2012","unstructured":"Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Skoromets A, Stolyarov I, Bass A, Sullivan H, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA (2012) Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 78(14):1069\u20131078. https:\/\/doi.org\/10.1212\/WNL.0b013e31824e8ee7","journal-title":"Neurology"},{"issue":"9856","key":"4975_CR6","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","volume":"380","author":"AJ Coles","year":"2012","unstructured":"Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA, investigators C-MI (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380(9856):1829\u20131839. https:\/\/doi.org\/10.1016\/S0140-6736(12)61768-1","journal-title":"Lancet"},{"issue":"11","key":"4975_CR7","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1212\/WNL.0000000000004313","volume":"89","author":"E Havrdova","year":"2017","unstructured":"Havrdova E, Arnold DL, Cohen JA, Hartung HP, Fox EJ, Giovannoni G, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Rodriguez CE, Jody D, Hogan RJ, Xenopoulos P, Panzara MA, Coles AJ, Care-Ms I, Investigators C (2017) Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy. Neurology 89(11):1107\u20131116. https:\/\/doi.org\/10.1212\/WNL.0000000000004313","journal-title":"Neurology"},{"issue":"10","key":"4975_CR8","doi-asserted-by":"publisher","first-page":"e823","DOI":"10.1212\/WNL.0000000000005067","volume":"90","author":"E Portaccio","year":"2018","unstructured":"Portaccio E, Annovazzi P, Ghezzi A, Zaffaroni M, Moiola L, Martinelli V, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Patti F, Solaro C, Bellantonio P, Uccelli A, Laroni A, Pasto L, Giannini M, Trojano M, Comi G, Amato MP, Society MSSGotIN (2018) Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: fetal risks. Neurology 90(10):e823\u2013e831. https:\/\/doi.org\/10.1212\/WNL.0000000000005067","journal-title":"Neurology"},{"key":"4975_CR9","doi-asserted-by":"crossref","unstructured":"Rog D, Oh J, Chambers C, Hellwig K, McCombe P, Otero S, Margolin DH, Daizadeh N, Compston DAS (2017) Pregnancy Outcomes in patients with RRMS treated with Alemtuzumab from the clinical development program. Paper presented at the 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Paris, France, 25\u201328 October 2017","DOI":"10.26226\/morressier.59a3eda9d462b8028d8956cb"},{"key":"4975_CR10","doi-asserted-by":"publisher","unstructured":"Leruez-Ville M, Foulon I, Pass R, Ville Y (2020) Cytomegalovirus infection during pregnancy: state of the science. Am J Obstet Gynecol. https:\/\/doi.org\/10.1016\/j.ajog.2020.02.018","DOI":"10.1016\/j.ajog.2020.02.018"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-020-04975-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-020-04975-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-020-04975-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T09:21:48Z","timestamp":1628155308000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-020-04975-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,15]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["4975"],"URL":"https:\/\/doi.org\/10.1007\/s10072-020-04975-5","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,15]]},"assertion":[{"value":"25 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Cinziavaleria Russo received personal compensation from Sanofi Genzyme and Merck Serono. Roberta Lanzillo received personal compensation from Bayer, Novartis, Almirall, Sanofi Genzyme, Biogen, Merck Serono, and TEVA for public speaking, editorial work, and advisory boards. Francesco Sacc\u00e0 received personal compensation from Almirall, Argenx, Avexis, Biogen, Forward Pharma, Merk, Mylan, Novartis, Pomona, Roche, Sanofi, and Teva for public speaking, editorial work, and advisory boards. Marcello Moccia has received research grants from ECTRIMS-MAGNIMS, UK MS Society, and Merck; honoraria from Biogen, Merck, Novartis, and Roche; and consultant fees from Veterans Evaluation Services. Carotenuto Antonio has received salary from Federico II University of Naples, research grants from ALMIRALL, and honoraria form Novartis, Merk, Merck, and Biogen. Vincenzo Brescia Morra received personal compensation from Bayer, Novartis, Almirall, Sanofi Genzyme, Biogen, Merck Serono, and TEVA for public speaking, editorial work, and advisory boards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent from each reported patient was collected.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and Informed consent"}}]}}